Presented by Dr Willem Lybaert (VITAZ, Sint-Niklaas & UZA, Antwerp, Belgium)
Recent progress in metastatic gastric cancer treatment has begun to shift the outlook for patients, particularly in the HER2-negative population. Traditionally, the median survival for patients metastatic gastric cancer did not exceed 12 months, with few effective therapies beyond cytotoxic chemotherapy. In recent years, however, the introduction of immune checkpoint inhibitors in the first line treatment for these patients has markedly improved outcomes.
In the, randomised, phase III KEYNOTE 859 study adding pembrolizumab to chemotherapy significantly improved the overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) in patients with HER2-negative advanced gastric/GEJ cancer. Updated results of this trial, with a median follow-up of about 4.5 years, solidify these findings and confirm the fact that the treatment effect of pembrolizumab was more pronounced in patients with higher levels of PD-L1 expression. In this video, Dr Willem Lybaert, medical oncologist at VITAZ in Sint Niklaas and the University Hospital Antwerp talks us through the key take aways of this update.
References:
Rha SY et al., ASCO 2025, #P-326
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in